Abstract
Comprehensive molecular profiling of primary Extra‐mammary Paget's Disease (EMPD) indicates that individually profiled cases harbor potentially targetable molecular alterations. EMPD shares some but not all molecular features with its mammary counterpart. Potential therapeutic targets in EMPD include steroid receptors (ER and AR), HER2, and PIK3CA signaling pathways, TOP2A amplification, and immune checkpoints (PD‐L1).